Warren Lucinda 4

What Happened
Lucinda Warren, Chief Business Officer of Cue Biopharma (CUE), received a grant of 250,000 shares as a derivative award (stock option/award) on April 9, 2026. The filing reports an acquisition price of $0.00 (derivative award), so no cash was paid at grant; no immediate sale or purchase occurred.

Key Details

• Transaction date: 2026-04-09; Form 4 filed 2026-04-10 (timely filing).
• Transaction type/code: A — Grant/award or other acquisition (derivative).
• Shares/units: 250,000 (reported at $0.00).
• Vesting: Becomes exercisable over four years — 25% vests on the one-year anniversary, remainder vests in equal semi-annual installments thereafter (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, or cashless exercise in the filing excerpt.

Context
This was a compensation-related option/award grant, not an open-market purchase or sale. Such awards are common for executives and vest over time; they do not represent an immediate cash investment by the insider. When options vest and are exercised in the future, that may result in reported purchases or sales at that time.